Skip to main content

Loading market data...

MDGL

Madrigal Pharmaceuticals, Inc.

NASDAQ • United states

$457.96

-$9.58

(-2.05%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Madrigal Pharmaceuticals, Inc. (MDGL)

Unavailable

Quotes may be delayed

$10.58B

Market Cap

338,287

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Madrigal Pharmaceuticals, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

12 Aug 2026

Madrigal Pharmaceuticals, Inc. reported A director or senior management change or compensation event

Madrigal Pharmaceuticals, Inc. filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.

30 Jul 2026

Madrigal Pharmaceuticals, Inc. filed Form 10-Q

Madrigal Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

30 Jul 2026

Madrigal Pharmaceuticals, Inc. reported Operating or financial results

Madrigal Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

29 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Madrigal Pharmaceuticals, Inc..

17 Jun 2026

Madrigal Pharmaceuticals, Inc. securities registration filing

Madrigal Pharmaceuticals, Inc. filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$292.73M

Total assets (USD)$1.24B

Total liabilities (USD)$720.92M

Shareholders' equity (USD)$523.72M

Long-term debt (USD)$340.79M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$364.25M	−$56.31M	−$57.94M	−$1.99	10-Q · 30 Jul 2026
Q1 2026	$311.34M	−$92.72M	−$94.39M	−$3.25	10-Q · 6 May 2026
Q4 2025	$321.08M	−$59.61M	−$58.58M	Unavailable	10-K · 19 Feb 2026
Q3 2025	$287.27M	−$113.98M	−$114.19M	−$4.01	10-Q · 4 Nov 2025
Q2 2025	$212.80M	−$47.20M	−$42.28M	−$1.50	10-Q · 5 Aug 2025
Q1 2025	$137.25M	−$79.31M	−$73.24M	−$2.61	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $683.67

49.3% upside potential

📈

Strong Buy

Unavailable

👍

Buy

10

⏸️

Hold

1

📉

Sell

0

11 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 20:49 UTC Targets range 533.00–962.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

11

Sep 2026

Sibold William John

Director, President and CEO

Open-market sale

$542.39 per share

5,221 shares

9

Sep 2026

Sibold William John

Director, President and CEO

Open-market sale

$535.59 per share

6,362 shares

17

Aug 2026

Kelley Shannon T

General Counsel

Open-market sale

$514.97 per share

664 shares

15

Aug 2026

REED JOHN C

Director

Grant or award

Unavailable per share

647 shares

20

Jul 2026

Sibold William John

Director, President and CEO

Open-market sale

$547.30 per share

2,500 shares

17

Jul 2026

Sibold William John

Director, President and CEO

Option exercise

Unavailable per share

50,000 shares

17

Jun 2026

Taub Rebecca

Director

Grant or award

Unavailable per share

454 shares

17

Jun 2026

Levy Richard S

Director

Grant or award

Unavailable per share

454 shares

17

Jun 2026

FOUSE JACQUALYN A

Director

Grant or award

Unavailable per share

454 shares

17

Jun 2026

Daly James M

Director

Grant or award

Unavailable per share

454 shares

Top Shareholders

Baker Bros. Advisors Lp

2,143,131 shares

0.067% change

6/30/2026

Janus Henderson Group Ltd.

2,018,647 shares

27.372% change

3/31/2026

Rtw Investments, Lp

1,993,687 shares

0% change

6/30/2026

Jupiter Topco Llc

1,936,099 shares

New% change

6/30/2026

Avoro Capital Advisors Llc

1,833,333 shares

0.833% change

6/30/2026

Vanguard Group Inc

1,808,894 shares

-0.174% change

12/31/2025

Paulson & Co. Inc.

1,340,020 shares

-3.747% change

6/30/2026

Blackrock, Inc.

1,200,770 shares

-23.026% change

6/30/2026

Vanguard Capital Management Llc

835,668 shares

1.031% change

6/30/2026

Wellington Management Group Llp

825,714 shares

18.815% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 20:49 UTC· 10 hours ago

Research coverage and investment tools

Madrigal Pharmaceuticals, Inc. (MDGL) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$457.96 on 21 Oct 2026. That is 29% of the way from its 52-week low of US$393.61 to its 52-week high of US$615.00. Its market capitalisation was US$10.58 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$364.25M	−$56.31M	−$57.94M	−$1.99	—	-15.5%	$19.08M	10-Q · 30 Jul 2026 (opens in a new tab)
Q1 2026	$311.34M	−$92.72M	−$94.39M	−$3.25	—	-29.8%	−$171.28M	10-Q · 6 May 2026 (opens in a new tab)
Q4 2025	$321.08M	−$59.61M	−$58.58M	Unavailable	—	-18.6%	−$133.07M	10-K · 19 Feb 2026 (opens in a new tab)
Q3 2025	$287.27M	−$113.98M	−$114.19M	−$4.01 R (restated)	—	-39.7%	$78.99M	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$212.80M	−$47.20M	−$42.28M	−$1.50 R (restated)	—	-22.2%	−$47.05M	10-Q · 5 Aug 2025 (opens in a new tab)
Q1 2025	$137.25M	−$79.31M	−$73.24M	−$2.61 R (restated)	—	-57.8%	−$88.89M	10-Q · 1 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/30/2026	−$1.99	−$2.55	+22.0%
Mar 2026	5/6/2026	−$3.25	−$3.61	+10.0%
Dec 2025	2/19/2026	−$2.57	$0.04	-6,525.0%
Sep 2025	11/4/2025	−$5.08	−$1.98	-156.6%

Cash and equivalents: $292.73M
Total assets: $1.24B
Total liabilities: $720.92M
Shareholders' equity: $523.72M
Long-term debt: $340.79M

8-K · 12 Aug 2026 · Management change

Madrigal Pharmaceuticals, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Madrigal Pharmaceuticals, Inc. filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.
10-Q · 30 Jul 2026

Madrigal Pharmaceuticals, Inc. filed Form 10-Q (opens in a new tab)

Madrigal Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 30 Jul 2026

Madrigal Pharmaceuticals, Inc. reported Operating or financial results (opens in a new tab)

Madrigal Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G/A · 29 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Madrigal Pharmaceuticals, Inc..
S-8 · 17 Jun 2026

Madrigal Pharmaceuticals, Inc. securities registration filing (opens in a new tab)

Madrigal Pharmaceuticals, Inc. filed a registration or prospectus document concerning securities.

Insider	Date	Transaction	Shares	Average price	Filing
Sibold William John Director, President and CEO	11 Sep 2026	Open-market sale (S)	−5,221	$542.39	Form 4 (opens in a new tab)
Sibold William John Director, President and CEO	9 Sep 2026	Open-market sale (S)	−6,362	$535.59	Form 4 (opens in a new tab)
Kelley Shannon T General Counsel	17 Aug 2026	Open-market sale (S)	−664	$514.97	Form 4 (opens in a new tab)
REED JOHN C Director	15 Aug 2026	Grant or award (A)	+647	—	Form 4 (opens in a new tab)
Sibold William John Director, President and CEO	20 Jul 2026	Open-market sale (S)	−2,500	$547.30	Form 4 (opens in a new tab)
Sibold William John Director, President and CEO	17 Jul 2026	Option exercise (M)	+50,000	—	Form 4 (opens in a new tab)
Taub Rebecca Director	17 Jun 2026	Grant or award (A)	+454	—	Form 4 (opens in a new tab)
Levy Richard S Director	17 Jun 2026	Grant or award (A)	+454	—	Form 4 (opens in a new tab)
FOUSE JACQUALYN A Director	17 Jun 2026	Grant or award (A)	+454	—	Form 4 (opens in a new tab)
Daly James M Director	17 Jun 2026	Grant or award (A)	+454	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Baker Bros. Advisors Lp	6/30/2026	2,143,131	0.067%
Janus Henderson Group Ltd.	3/31/2026	2,018,647	27.372%
Rtw Investments, Lp	6/30/2026	1,993,687	0%
Jupiter Topco Llc	6/30/2026	1,936,099	New
Avoro Capital Advisors Llc	6/30/2026	1,833,333	0.833%
Vanguard Group Inc	12/31/2025	1,808,894	-0.174%
Paulson & Co. Inc.	6/30/2026	1,340,020	-3.747%
Blackrock, Inc.	6/30/2026	1,200,770	-23.026%
Vanguard Capital Management Llc	6/30/2026	835,668	1.031%
Wellington Management Group Llp	6/30/2026	825,714	18.815%

Previous close: 467.54 USD
Day range: 456.65 – 481.87 USD
52-week range: 393.61 – 615.00 USD
Volume: 338,287
Market cap: $10.58B
Average volume: 256,493
EPS (FY 2025, diluted): −10.15 USD
Shares outstanding: 23.10M
Beta (5Y monthly): -1.04

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 11 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:37 UTC· 36 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for MDGL yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.